Several other brokerages have also recently commented on AITB. Ladenburg Thalmann Financial Services began coverage on shares of AIT Therapeutics in a research report on Monday, August 7th. They set a buy rating for the company. Laidlaw began coverage on shares of AIT Therapeutics in a research report on Thursday, August 24th. They set a buy rating and a $16.00 target price for the company.
AIT Therapeutics (AITB) opened at $5.80 on Friday. AIT Therapeutics has a 1-year low of $4.32 and a 1-year high of $10.00.
WARNING: This piece was first published by Community Financial News and is the property of of Community Financial News. If you are accessing this piece on another site, it was copied illegally and republished in violation of US and international trademark & copyright laws. The correct version of this piece can be accessed at https://www.com-unik.info/2017/12/05/roth-capital-analysts-give-ait-therapeutics-aitb-a-16-00-price-target.html.
AIT Therapeutics, Inc, formerly KokiCare, Inc, is a shell company. The Company is engaged in the discovery and planning phase to develop a real-time, software as a service (SaaS)-based enterprise software application to manage the integration, planning, tracking and management of healthcare assets, which include people, supplies, clinical data, relationships and financial resources of healthcare organizations.
What are top analysts saying about AIT Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for AIT Therapeutics Inc. and related companies.